Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Oligo safety working group exaggerated pharmacology subcommittee consensus document.

Kornbrust D, Cavagnaro J, Levin A, Foy J, Pavco P, Gamba-Vitalo C, Guimond A.

Nucleic Acid Ther. 2013 Feb;23(1):21-8. doi: 10.1089/nat.2012.0399. Epub 2013 Jan 4.

PMID:
23289535
2.

Recommendations for safety pharmacology evaluations of oligonucleotide-based therapeutics.

Berman CL, Cannon K, Cui Y, Kornbrust DJ, Lagrutta A, Sun SZ, Tepper J, Waldron G, Younis HS.

Nucleic Acid Ther. 2014 Aug;24(4):291-301. doi: 10.1089/nat.2013.0477. Epub 2014 Jun 19. Review.

PMID:
24946015
3.

Therapeutic oligonucleotides.

Goodchild J.

Methods Mol Biol. 2011;764:1-15. doi: 10.1007/978-1-61779-188-8_1. Review.

PMID:
21748630
4.

Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.

EFSA GMO Panel Working Group on Animal Feeding Trials.

Food Chem Toxicol. 2008 Mar;46 Suppl 1:S2-70. doi: 10.1016/j.fct.2008.02.008. Epub 2008 Feb 13. Review.

PMID:
18328408
5.

Liver as a target for oligonucleotide therapeutics.

Sehgal A, Vaishnaw A, Fitzgerald K.

J Hepatol. 2013 Dec;59(6):1354-9. doi: 10.1016/j.jhep.2013.05.045. Epub 2013 Jun 12.

6.

Designing chemically modified oligonucleotides for targeted gene silencing.

Deleavey GF, Damha MJ.

Chem Biol. 2012 Aug 24;19(8):937-54. doi: 10.1016/j.chembiol.2012.07.011. Review.

7.

First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity.

Dyke CK, Steinhubl SR, Kleiman NS, Cannon RO, Aberle LG, Lin M, Myles SK, Melloni C, Harrington RA, Alexander JH, Becker RC, Rusconi CP.

Circulation. 2006 Dec 5;114(23):2490-7. Epub 2006 Nov 13.

8.

Discovery and development of therapeutic aptamers.

Bouchard PR, Hutabarat RM, Thompson KM.

Annu Rev Pharmacol Toxicol. 2010;50:237-57. doi: 10.1146/annurev.pharmtox.010909.105547. Review.

PMID:
20055704
9.

Recommendations of the Oligonucleotide Safety Working Group's Formulated Oligonucleotide Subcommittee for the Safety Assessment of Formulated Oligonucleotide-Based Therapeutics.

Marlowe JL, Akopian V, Karmali P, Kornbrust D, Lockridge J, Semple S.

Nucleic Acid Ther. 2017 Aug;27(4):183-196. doi: 10.1089/nat.2017.0671. Epub 2017 Jun 13.

PMID:
28609186
10.

Considerations for assessment of reproductive and developmental toxicity of oligonucleotide-based therapeutics.

Cavagnaro J, Berman C, Kornbrust D, White T, Campion S, Henry S.

Nucleic Acid Ther. 2014 Oct;24(5):313-25. doi: 10.1089/nat.2014.0490. Epub 2014 Aug 19. Review.

PMID:
25137397
11.

[Oligonucleotide therapeutics].

Matsuda Y, Nakamura Y.

Nihon Rinsho. 2012 Nov;70 Suppl 8:393-7. Japanese. No abstract available.

PMID:
23513872
12.

OSWG Recommendations for Genotoxicity Testing of Novel Oligonucleotide-Based Therapeutics.

Berman CL, Barros SA, Galloway SM, Kasper P, Oleson FB, Priestley CC, Sweder KS, Schlosser MJ, Sobol Z.

Nucleic Acid Ther. 2016 Apr;26(2):73-85. doi: 10.1089/nat.2015.0534. Epub 2016 Mar 15. Review.

PMID:
26978711
13.

Clinical expert panel on monitoring potential lung toxicity of inhaled oligonucleotides: consensus points and recommendations.

Alton EW, Boushey HA, Garn H, Green FH, Hodges M, Martin RJ, Murdoch RD, Renz H, Shrewsbury SB, Seguin R, Johnson G, Parry JD, Tepper J, Renzi P, Cavagnaro J, Ferrari N.

Nucleic Acid Ther. 2012 Aug;22(4):246-54. doi: 10.1089/nat.2012.0345. Epub 2012 Jul 18.

14.

Therapeutic applications of aptamers.

Kaur G, Roy I.

Expert Opin Investig Drugs. 2008 Jan;17(1):43-60. Review.

PMID:
18095918
15.

The versatility of oligonucleotides as potential therapeutics.

Eckstein F.

Expert Opin Biol Ther. 2007 Jul;7(7):1021-34. Review.

PMID:
17665991
16.

Antisense and/or immunostimulatory oligonucleotide therapeutics.

Agrawal S, Kandimalla ER.

Curr Cancer Drug Targets. 2001 Nov;1(3):197-209. Review.

PMID:
12188879
17.

Building oligonucleotide therapeutics using non-natural chemistries.

Wilson C, Keefe AD.

Curr Opin Chem Biol. 2006 Dec;10(6):607-14. Epub 2006 Oct 16. Review.

PMID:
17049298
18.

Aptamers: the emerging class of future anticoagulation for vascular disease.

Kuliczkowski W, Floyd J, Malinin A, Serebruany V.

Expert Rev Cardiovasc Ther. 2010 Apr;8(4):503-7. doi: 10.1586/erc.09.182.

PMID:
20397824
19.

[Application of functional RNAs in human diseases].

Tanaka Y, Kozu T.

Tanpakushitsu Kakusan Koso. 2006 Nov;51(14 Suppl):2235-7. Review. Japanese. No abstract available.

PMID:
17471945
20.

MicroRNA replacement therapy for cancer.

Henry JC, Azevedo-Pouly AC, Schmittgen TD.

Pharm Res. 2011 Dec;28(12):3030-42. doi: 10.1007/s11095-011-0548-9. Epub 2011 Aug 31. Review.

PMID:
21879389

Supplemental Content

Support Center